Lamivudine/zidovudine

Lamivudine/zidovudine
Combination of
Lamivudine	Nucleoside analogue reverse transcriptase inhibitor
Zidovudine	Nucleoside analogue reverse transcriptase inhibitor
Clinical data
Trade names	Combivir
AHFS/Drugs.com	Professional Drug Facts
MedlinePlus	a601066
License data	EU EMA: by INN; US DailyMed: Lamivudine_and_zidovudine;
Pregnancy; category	AU: B3;
Routes of; administration	By mouth
ATC code	J05AR01 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); US: WARNINGRx-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
CAS Number	165456-81-5;
PubChem CID	160352;
ChemSpider	21106283 ;
KEGG	D07507;
NIAID ChemDB	031479;
CompTox Dashboard (EPA)	DTXSID90167954 ;
	(verify)

Lamivudine/zidovudine, sold under the brand name Combivir among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It contains two antiretroviral medications, lamivudine and zidovudine. It is used together with other antiretrovirals. It is taken by mouth twice a day.

Common side effects include headache, feeling tired, nausea, diarrhea, and fever. Severe side effects may include bone marrow suppression, muscle damage, worsening of hepatitis B if previously infected, high blood lactate and liver enlargement. It may be part of a recommended treatment during pregnancy. The medications are both of the nucleoside reverse transcriptase inhibitor (NRTI) class. They work by blocking the action of the enzyme, reverse transcriptase, that the virus requires to reproduce.

Lamivudine/zidovudine was approved for medical use in the United States in 1997, and in the European Union in 1998. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.